Neurodazine作为一种神经源性诱导剂，能够促进多能干细胞的神经发生。
Cas No.:937807-66-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Neurodazine functions as a neurogenic inducer, capable of promoting neurogenesis in pluripotent stem cells[1]. Neurodazine facilitates neurogenesis by activating the Wnt and Shh signaling pathways, while selectively inhibiting astrocyte differentiation in P19 cells[2].
In vitro, treatment of human SH-SY5Y neuroblastoma cells and murine Neuro-2a neuroblastoma cells with Neurodazine (2.5-5μM) for 10 days, Neurodazine significantly induced neuronal differentiation. This effect, mediated through the activation of Wnt and Shh signaling pathways, upregulated the expression of neuron-specific markers (Tuj1, MAP2, NF200, NSE) and promoted the expression of glutamate receptor subtypes (NMDAR1, GluK4, mGluR6)[3]. Co-treatment of human fibroblasts (hNF) with Neurodazine (2.5–4μM) and the hedgehog pathway inhibitor HPI-1 for 10 days, Neurodazine induced the transdifferentiation of fibroblasts into dopaminergic neuron-like cells, upregulated tyrosine hydroxylase (TH) and dopamine secretion, activated the autophagy pathway (increased expression of LC3, ATG5, ATG12), and inhibited apoptosis-related gene expression[4].
In vivo, intraplantar injection of Neurodazine (5μg) combined with complete Freund's adjuvant (CFA) in C57BL/6J mice during the juvenile stage (P21-P29), Neurodazine significantly enhanced resilience to anxiety-like behaviors induced by subthreshold acute restraint stress in adulthood (P90) and reduced serum corticosterone levels. Neurodazine also markedly ameliorated neurogenesis deficits in the hippocampal ventral dentate gyrus (vDG)[5].
References:
[1] Pérez-Caaveiro C, Pérez Sestelo J, Martínez MM, et al. Triorganoindium reagents in selective palladium-catalyzed cross-coupling with iodoimidazoles: synthesis of neurodazine. J Org Chem. 2014 Oct 17;79(20):9586-93.
[2] Kim GH, Halder D, Park J, et al. Imidazole-based small molecules that promote neurogenesis in pluripotent cells. Angew Chem Int Ed Engl. 2014 Aug 25;53(35):9271-4.
[3] Sorraksa N, Kaokaen P, Kunhorm P, et al. Rapid induction of dopaminergic neuron-like cells from human fibroblasts by autophagy activation with only 2-small molecules. 3 Biotech. 2024 Apr;14(4):115.
[4] Halder D, Kim GH, Shin I. Synthetic small molecules that induce neuronal differentiation in neuroblastoma and fibroblast cells. Mol Biosyst. 2015 Oct;11(10):2727-37.
[5] Yang C, Hu B, Gao Y, et al. Pain experience in juveniles promotes vulnerability to anxiety-like behaviors in adult mice by suppressing hippocampal neurogenesis. Biochem Biophys Res Commun. 2025 Aug 15;775:152170.
Neurodazine作为一种神经源性诱导剂，能够促进多能干细胞的神经发生[1]。Neurodazine通过激活Wnt和Shh信号通路以促进神经发生，并选择性抑制P19细胞的星形胶质细胞分化[2]。
在体外，Neurodazine（2.5-5μM）处理人源SH-SY5Y神经母细胞瘤细胞和鼠源Neuro-2a神经母细胞瘤细胞10天，Neurodazine通过激活Wnt和Shh信号通路，显著诱导神经元分化，上调神经元特异性标志物（Tuj1、MAP2、NF200、NSE）的表达，并促进谷氨酸受体亚型（NMDAR1、GluK4、mGluR6）的表达[3]。Neurodazine（2.5–4μM）与hedgehog通路抑制剂HPI-1联合处理人源成纤维细胞（hNF）10天，Neurodazine与HPI-1协同诱导成纤维细胞向多巴胺能神经元样细胞转分化，上调酪氨酸羟化酶（TH）和多巴胺分泌，并激活自噬通路（LC3、ATG5、ATG12表达上调），抑制凋亡相关基因表达[4]。
在体内，在C57BL/6J小鼠幼年期（P21-P29），Neurodazine（5μg）联合完全弗氏佐剂（CFA）腹腔注射处小鼠，Neurodazine显著增强了小鼠在成年期（P90）对亚阈值急性束缚应激诱导的焦虑样行为的抵抗力，降低血清皮质酮水平。Neurodazine显著改善了海马腹侧齿状回（vDG）的神经发生缺陷[5]。
| Cell experiment [1]: | |
Cell lines | SH-SY5Y human neuroblastoma cells, Neuro-2a mouse neuroblastoma cells, and NIH3T3 mouse fibroblast cells |
Preparation Method | SH-SY5Y and Neuro-2a cells were maintained in MEM or DMEM supplemented with 10% FBS, penicillin-streptomycin, and L-glutamine at 37°C with 5% CO₂. NIH3T3 fibroblasts were cultured in DMEM with 10% FBS and antibiotics. Cells were treated with Neurodazine at 2.5–5μM for 8–10 days under non-adherent conditions to induce aggregation, followed by differentiation in serum-reduced media containing Neurodazine. |
Reaction Conditions | 2.5–5μM; 8–10 days. |
Applications | Neurodazine significantly promoted neuronal differentiation in neuroblastoma and fibroblast cells, evidenced by upregulated expression of neuron-specific markers (Tuj1, MAP2, NF200, NSE) at both protein and gene levels. Neurodazine treatment induced morphological changes resembling neurons, with increased branching and expression of glutamate receptor isoforms (e.g., NMDAR1, mGluR6 in SH-SY5Y cells; GluK4, mGluR3/5/7 in Neuro-2a cells). |
| Animal experiment [2]: | |
Animal models | C57BL/6 mice |
Preparation Method | Juvenile mice (postnatal days P21–P29) received intraplanar injections of complete Freund’s adjuvant (CFA) into the right hind paw to induce inflammatory pain, with Neurodazine (5μg) co-administered alongside CFA. On P90, mice were subjected to a 30-min acute restraint stress (ARS) and subsequently assessed for anxiety-like behaviors and neurobiological changes. |
Dosage form | 5μg; i.p.; administered on P21, P23, P25, P27, and P29. |
Applications | Neurodazine administration significantly enhanced resilience to anxiety-like behaviors in CFA-treated mice, alongside reduced serum corticosterone levels following subthreshold ARS. Neurodazine treatment restored hippocampal neurogenesis deficits in the ventral dentate gyrus (vDG) |
References: | |
| Cas No. | 937807-66-4 | SDF | |
| 化学名 | 2-(5-(3-chlorophenyl)furan-2-yl)-4,5-bis(4-methoxyphenyl)-1H-imidazole | ||
| Canonical SMILES | ClC1=CC(C2=CC=C(C3=NC(C(C=C4)=CC=C4OC)=C(C(C=C5)=CC=C5OC)N3)O2)=CC=C1 | ||
| 分子式 | C27H21ClN2O3 | 分子量 | 456.92 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 20 mg/ml,Ethanol: 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1886 mL | 10.9428 mL | 21.8857 mL |
| 5 mM | 437.7 μL | 2.1886 mL | 4.3771 mL |
| 10 mM | 218.9 μL | 1.0943 mL | 2.1886 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet